SCHEMBL4479377

SCHEMBL4479377

CSc1c(C(=O)O)nc(-c2ccc(Cl)cc2Cl)n1-c1ccc(Cl)cc1

nearest known ligand 0.69

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 19/20 0.69
CNR2 P34972 16/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4065973 0.88 CNR1 (0.69) CNR1CNR2
SCHEMBL3680322 0.85 CNR1 (0.71) CNR1CNR2
SCHEMBL4479776 0.85 CNR1 (0.77) CNR1CNR2
SCHEMBL4474146 0.82 CNR1 (1.00) CNR1CNR2
SCHEMBL6105037 0.81 CNR1 (0.66) CNR1CNR2
SCHEMBL4492538 0.81 CNR1 (1.00) CNR1CNR2
SCHEMBL3683841 0.81 CNR1 (1.00) CNR1CNR2
SCHEMBL675613 0.81 CNR1 (0.79) CNR1CNR2
SCHEMBL4486029 0.80 CNR1 (0.68) CNR1CNR2
SCHEMBL6102985 0.80 CNR1 (0.67) CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101431998-A Containing CBxPharmaceutical compositions of cannabinoid receptor modulators and potassium channel modulators SOLVAY PHARM GMBH (DE) 2009-05-13 CN claimed
CN-101431994-A Use of CBx cannabinoid receptor modulators as potassium channel modulators SOLVAY PHARM GMBH (DE) 2009-05-13 CN claimed
CN-101426197-A Dynamic content distributing customer terminal in TD-SCDMA mobile terminal SHANGHAI WINGTECH ELECTRONIC T (CN) 2009-05-06 CN disclosed
US-7524867-B2 Tetrasubstituted imidazole derivatives as cannabinoid CB1 receptor modulators with a high CB1/CB2 receptor subtype selectivity SOLVAY PHARMACEUTICALS, B.V. (NL) 2009-04-28 US disclosed
EP-1756066-B1 TETRASUBSTITUTED IMIDAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR MODULATORS WITH A HIGH CB1/CB2 RECEPTOR SUBTYPE SELECTIVITY SOLVAY PHARM BV (NL) 2008-08-20 EP disclosed
EP-1756066-A1 TETRASUBSTITUTED IMIDAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR MODULATORS WITH A HIGH CB1/CB2 RECEPTOR SUBTYPE SELECTIVITY Solvay Pharmaceuticals B.V. (NL) 2007-02-28 EP disclosed
US-7109216-B2 1H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity SOLVAY PHARMACEUTICALS B.V. (NL) 2006-09-19 US disclosed
WO-2005118553-A1 TETRASUBSTITUTED IMIDAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR MODULATORS WITH A HIGH CB1/CB2 RECEPTOR SUBTYPE SELECTIVITY SOLVAY PHARMACEUTICALS B.V. (NL) 2005-12-15 WO disclosed
US-20050267161-A1 Tetrasubstituted imidazole derivatives as cannabinoid CB1 receptor modulators with a high CB1/CB2 receptor subtype selectivity SOLVAY PHARMACEUTICALS B.V. 2005-12-01 US disclosed
US-20050054679-A1 1 H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity SOLVAY PHARMACEUTICALS B.V. 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050267161-A1 Tetrasubstituted imidazole derivatives as cannabinoid CB1 receptor modulators with a high CB1/CB2 receptor subtype selectivity CNR1, CNR2, TRPV1 CNR1 1/4885CNR2 2/4885
US-20050054679-A1 1 H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity CNR1, CNR2, HRH4 CNR1 1/4885CNR2 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.